Properties of Bisphosphonates in the 13762 Rat Mammary Carcinoma Model of Tumor-Induced Bone Resorption

Clinical Cancer Research

Volumn 9, Issue 15, 2003, Pages 5705-5713

  Alvarez, Enrique ^d   Westmore, Michael ^a   Galvin, Rachelle J Sells ^a   Clapp, Crystal L ^a   Considine, Eileen L ^a   Smith, Shawn J ^a   Keyes, Kristan ^a   Iversen, Philip W ^a   Delafuente, Dawn M ^a   Sulaimon, Shola ^a   Zambrano, Carmen ^a   Ma, Linda ^a   Sato, Masahiko ^a   Martin, T John ^b   Teicher, Beverly A ^c   Galbreath, Elizabeth J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c GENZYME CORPORATION   (United States)

^d CURAGEN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CISPLATIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PAMIDRONIC ACID; RISEDRONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE METASTASIS; BONE MINERAL; BREAST CARCINOMA; CANCER CELL; CANCER MODEL; CELL CULTURE; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG EFFICACY; FEMALE; IC 50; IMMUNOHISTOCHEMISTRY; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRABECULAR BONE;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE RESORPTION; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DIPHOSPHONATES; DISEASE PROGRESSION; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASM METASTASIS; OSTEOLYSIS; PARATHYROID HORMONE-RELATED PROTEIN; RATS; RATS, INBRED F344; TRANSFORMING GROWTH FACTOR BETA;

EID: 10744225732     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Coleman, R. E. Management of bone metastases. Oncologist, 5: 463-470, 2000.
2. Coleman, R. E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev., 27: 165-176, 2001.
3. Thompson, S. W. N., and Tonge, D. Bone cancer gain without pain. Nat. Med., 6: 504-505, 2000.
4. Honore, P., Luger, N. M., Sabino, M. A., Schwei, M. J., Rogers, S. D., Mach, D. B., O'Keefe, P. F., Ramnaraine, M. L., Clohisy, D. R., and Mantyh, P. W. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat. Med., 6: 521-528, 2000.
5. Diener, K. M. Bisphosphonates for controlling pain from metastatic bone disease. Am J. Health-System Pharm., 53: 1917-1927, 1996.
6. Diel, I. J., and Mundy, G. R. Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical reviews. Br. J. Cancer, 82: 1381-1386. 2000.
7. Berenson, J. R. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials. Semin. Oncol., 28: 25-34, 2001.
8. Boissier, S., Ferreras, M., Peyruchaund, O., Magnetto, S., Ebetino, F. H., Colombel, M., Delmas, P., Delaisse, J. M., and Clezardin, P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res., 60: 2949-2954, 2000.
9. Coleman, R. E., and Seaman, J. J. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Semin. Oncol., 28: 11-16, 2001.
10. Kanis, J. A. Bone and cancer: phatophysiology and treatment of metastases. Bone, 17: 101s-105s, 1995.
11. Orr, F. W., Sanchez-Sweatman, O. H., Kostenuik, P., and Singh, G. Tumor-bone interactions in skeletal metastasis. Clin. Orthop. Relat. Res., 312: 19-33, 1995.
12. Inoue, D., and Matsumoto, T. Parathyroid hormone-related peptide and bone: pathological and physiological aspects. Biomed. Pharmacother., 54 (Suppl. 1): 32s-41s, 2000.
13. Iddon, J., Byrne, G., and Bundred, N. J. Bone metastasis in breast cancer: the role of parathyroid hormone related protein. Surg. Oncol., 8: 13-25, 1999.
14. Guise, T. A., and Mundy, G. R. Cancer and bone. Endocr. Rev., 19: 18-54, 1998.
15. Guise, T. A., Yin, J. J., Taylor, S. D., Kumagai, Y., Dallas, M., Boyce, B. F., Yoneda, T., and Mundy, G. R. Evidence for a causal role of parathyroid hormone related protein in the pathogenesis of human breast cancer mediated osteolysis. J. Clin. Investig., 98: 1544-1549, 1996.
16. Clohisy, D. R., Perkins, S. L., and Ramnaraine, M. L. Review of cellular mechanisms of tumor osteolysis. Clin. Orthop. Relat. Res., 373: 104-114, 2000.
17. Clohisy, D. R., and Ramnaraine, M. L. Osteoclasts are required for bone tumors to grow and destroy bones. J. Orthop. Res., 16: 660-666, 1998.
18. Chirguin, J. M., and Guise, T. A. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit. Rev. Eukaryotic Gene Expression, 12: 159-178, 2000.
19. Boyce, B. F., Yoneda, T., and Guise, T. A. Factors regulating the growth of metastatic cancer in bone. Endocr. Relat. Cancer, 6: 333-347, 1999.
20. Arguello, F., and Cohen, H. J. Structural and microenvironmental bone marrow factors involved in the pathogenesis of bone metastasis, In: W. F. Orr and G. Singh (eds.), Bone Metastasis: Mechanisms and Pathophysiology, pp. 31-45. Philadelphia: Lippincott, Williams & Wilkins, 1996.
21. Yoneda, T., Sasaki, A., and Mundy, G. R. Osteolytic bone metastasis in breast cancer. Breast Cancer Res. Treat., 32: 73-84, 1994.
22. Teitelbaum, S. L. Bone resorption by osteoclasts. Science (Wash. DC), 289: 1504-1508, 2000.
23. Rabbani, S. A., Gladu, J., Harakidas, P., Jamison, B., and Goltzman, D, Over-production of parathyroid-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int. J. Cancer, 80: 257-264, 1999.
24. Moseley, J. M., and Gillespie, M. T. Parathyroid hormone-related protein. Crit. Rev. Clin. Lab. Sci., 32: 299-343, 1995.
25. Grill, V., Ho, P., Body, J. J., Johanson, N., Lee, S. C., Kukreja, S. C., Moseley, J. M., and Martin, T. J. Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer. J. Clin. Endocrinol. Metab., 73: 1309-1315, 1991.
26. Centrella, M., Horowitz, M. C., Wozney, J. M., and McCarthy, T. L. Transforming growth factor-β gene family members and bone. Endocr. Rev., 15: 27-39, 1994.
27. Oursler, M. J. Osteoclast synthesis and secretion and activation of latent transforming growth factor β. J. Bone Miner. Res., 9: 443-452, 1994.
28. Oreffo, R. O., Mundy, G. R., Seyedin, S. M., and Bonewald, L. F. Activation of the bone-derived latent TGF β complex by isolated osteoclasts. Biochem. Biophys. Res. Commun., 158: 817-823, 1989.
29. Pfeilschifter, J., and Mundy, G. R. Modulation of type β transforming growth factor activity in bone cultures by osteotropic hormones. Proc. Natl. Acad. Sci. USA, 84: 2024-2028, 1987.
30. Hoodless, P., and Wrana, J. L. Mechanisms and function of signalling by the TGFβ superfamily. Curr. Top. Microbiol. Immunol., 228: 235-272, 1998.
31. Massague, J. TGFβ signal transduction. Annu. Rev. Biochem., 67: 753-791, 1998.
32. Alcantara, A., Montalvo-Figueroa, J. A., Toro, S., and Aguilo, F. An update on the discovery, pathophysiological actions, clinical manifestations and possible physiology of parathyroid related peptide. PR. Health Sci. J., 16: 15-22, 1997.
33. Martin, T. J., Lam, M. H. C., Kartsogiannis, V., and Gillespie, M. T. Parathyroid hormone-related protein. In: E. Canalis (ed.), Skeletal Growth Factors, pp. 335-354. Philadelphia: Lippincott Williams & Wilkins, 2000.
34. Yin, J. J., Selander, K., Chirgwin, J. M., Dallas, M., Grubbs, B. G., Weiser, R., Massague, J., Mundy, G. R., and Guise, T. A. TGFβ signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Investig., 103: 197-206, 1999.
35. Segaloff, A. Recent progress in hormone research, hormones and breast cancer. Proc. Lauretian Hormone Conference, 22: 351-374, 1966.
36. Neri, A., Welch, D., Takanori, K., and Nicolson, G. L. Development and biological properties of malignant cell sublines and clones of a spontaneously metastasizing rat adenocarcinoma. J. Natl. Cancer Inst. (Bethesda), 68, 507-517, 1982
37. Stanko, R. T., Mullick, P., Clarke, M. R., Contis, L. C., Janosky, J. E., and Ramasastry, S. S. Pyruvate inhibits growth of mammary adenocarcinoma 13762 in rats. Cancer Res., 54: 1004-1007, 1994.
38. Ramasastry, S. S., Weinstein, L. W., Zerbe, A. Narayanan, K., LaPietra, D., and Futrell, J. W. Regression of local and distant tumor growth by tissue expansion: an experimental study of mammary carcinoma 13762 in rats. Plast. Reconstr. Surg., 87: 1-7, 1991.
39. Bogden, A. E., Esber, H. J., Taylor, D. J., and Gray, J. H. Comparative study on the effects of surgery, chemotherapy and immunotherapy, alone and in combination on metastasis of the 13762 mammary adenocarcinoma. Cancer Res., 34: 1627-1621, 1974.
40. Teicher, B. A., Alvarez Sotomayor, E., Dupuis, N. P., Kusumoto, T., and Menon, K. Reduced oxygenation in a rat mammary carcinoma after chemo- or radiation therapy and reoxygenation with perflubron emulsion/carbogen breathing. J. Cancer Res. Clin. Oncol., 120: 593-598, 1994.
41. Teicher, B. A., Dupuis, N. P., Robinson, M. F., Kusumoto, T., Liu, M., and Menon, K. Reduced oxygenation in a rat mammary carcinoma post-radiation and reoxygenation with at perfluoro emulsion/carbogen breathing. In Vivo, 8: 125-132, 1994.
42. Kakeji, Y., Maehara, Y., Ikebe, M., and Teicher, B. A. Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-β levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 37: 1115-1123, 1997.
43. Danks, J. A., Ebeling, P. R., Hayman, J. A., Diefenbach-Jagger, H., Collier, F., Grill, V., Southby, J., Moseley, J. M., Chou, S. T., and Martin, T. J. Immunohistochemical localization of parathyroid hormone-related protein in parathyroid adenoma and hyperplasia. J. Pathol., 161: 27-33, 1990.
44. Mundy, G. R. Cytokines, growth factors and malignancy. In: E. Canalis (ed.), Skeletal Growth Factors, pp. 431-442. Philadelphia: Lippincott Williams & Wilkins, 2000.
45. Arguello, F., Baggs, R. B., and Frantz, C. N. A murine model of experimental metastasis to bone and bone marrow. Cancer Res., 48: 6876-6881, 1988.
46. Miki, T., Yano, S., Hanibuchi, M., and Sone, S. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (sbc-5) cells in natural killer cell-depleted scid mice. Oncol. Res., 12: 209-217, 2000.
47. Tamura, H., Ishii, S., Ikeda, T., Wada, N., Enomoto, K., and Kitajima, M. Therapeutic efficacy of pamidronate in combination with chemotherapy to bone metastasis of breast cancer in a rat model. Surg. Oncol., 5: 141-147, 1996.
48. Blomme, E. A. G., Dougherty, K. M., Pienta, K. J., Capen, C. C., Rosol, T. J., and McCauley, L. K. Skeletal metastasis of prostate adenocarcinoma in rats: morphometric analysis and role of parathyroid hormone-related protein. Prostate, 39: 187-197, 1999.
49. Yoneda, T., Williams, P. J., Hiraga, T., Niewolna, M., and Nishimura, R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J. Bone Miner. Res., 16: 1486-1495, 2001.
50. Juraschek, M., Seibel, M. J., Woitge, H. W., Krempien, B., and Bauss, F. Association between histomorphometry and biochemical markers of bone turnover in a longitudinal rat model of parathyroid hormone-related peptide (PTHrP) mediated tumor osteolysis. Bone, 26: 475-483, 2000.
51. Wingen, F., Eichmann, T., Manegold, C., and Krempien, B. Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat. J. Cancer Res. Clin. Oncol., 111: 35-41, 1986.
52. Higara, T., Williams, P. J., Mundy, G. R., and Yoneda, T., The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastasis. Cancer Res., 61: 4418-4424, 2001.
53. Fleisch, H. Bisphosphonates: mechanism of action. Endocr. Rev., 19: 80-100, 1998.
54. Clezardin, P., Gligorov, J., and Delmas, P. Mechanisms of action of bisphosphonates on tumor cells and prospects for use in the treatment of malignant osteolysis. Joint Bone Spine, 67: 22-29, 2000.
55. Diel, I. J. Antitumor effects of bisphosphonates: first evidence and possible mechanisms. Drugs, 59: 391-399, 2000.
56. Green, J. R. Anti-tumor potential of bisphosphonates. Medizinische Klinik, 95: 23-28, 2000.
57. Sato, M., Grasser, W., Endo, N., Akins, R., Simmons, H., Thompson, D. D., Golub, E., and Rodan, G. A. Bisphosphonate action Alendronate localization in rat bone and effects on osteoclast ultrastructure. J. Clin. Investig., 88: 2095-2105, 1991.